Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
496
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

452
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
452
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

635
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
635

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 4-km long-term (1952-2025) daily hydrometeorological dataset for the western United States.

Scientific data·2026
Same author

The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.

Alimentary pharmacology & therapeutics·2026
Same author

Real-World Effectiveness of Upadacitinib for Perianal Crohn's Disease: A Multicenter Retrospective Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

One-third of asymptomatic youth baseball players exhibit ulnar collateral ligament sub-apophyseal avulsions.

Journal of shoulder and elbow surgery·2026
Same author

One patient, one destiny: A cluster analysis of the Parkinson's progression Markers Initiative (PPMI) cohort.

Clinical parkinsonism & related disorders·2026
Same author

Prevalence of Capitellar Osteochondral Abnormalities in Healthy Youth Gymnasts: An Ultrasound Study.

Orthopaedic journal of sports medicine·2026
Same journal

Management of Common Bile Duct Stones: Current Approaches and Evolving Endoscopic Strategies.

Current gastroenterology reports·2026
Same journal

Solitary Rectal Ulcer Syndrome Revisited: A Comprehensive Narrative Review.

Current gastroenterology reports·2026
Same journal

The Microbiome and Esophageal Disease: Where Are We Now?

Current gastroenterology reports·2026
Same journal

Fermented Durian Tempoyak as a Source of Probiotics for Colorectal Cancer Prevention through Gut Microbiome Modulation.

Current gastroenterology reports·2026
Same journal

A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.

Current gastroenterology reports·2026
Same journal

The Role of Endoscopic Ultrasound in the Diagnosis and Management of Congenital Gastrointestinal and Pancreaticobiliary Conditions.

Current gastroenterology reports·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.8K

New Kids on the Block: IL-23 Inhibitors in IBD Management.

Jacob Jones1, Jeevin Sandhu2, Kara Jones3

  • 1Division of Gastroenterology, Brooke Army Medical Center, 3551 Roger Brooke Drive Ft. Sam, Houston, TX, 78234, USA.

Current Gastroenterology Reports
|October 22, 2025
PubMed
Summary
This summary is machine-generated.

Interleukin-23 (IL-23) p19 inhibitors demonstrate efficacy and safety in managing Inflammatory Bowel Disease (IBD). This new class of biologics offers promising therapeutic options, including potential dual therapy approaches.

Keywords:
Biologic therapyCrohn’s diseaseIL23Inflammatory bowel diseaseP19 inhibitorsUlcerative colitis

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.9K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

400

Related Experiment Videos

Last Updated: Jan 14, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.8K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.9K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

400

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Inflammatory Bowel Disease (IBD) encompasses chronic conditions like Crohn's disease and ulcerative colitis.
  • Current IBD management involves various therapeutic strategies, with a continuous need for novel and effective treatments.

Purpose of the Study:

  • To review the efficacy and safety of Interleukin-23 (IL-23) p19 inhibitors for Inflammatory Bowel Disease (IBD) management.
  • To assess the role of IL-23p19 inhibitors within the existing therapeutic landscape for IBD.

Main Methods:

  • Systematic review of clinical trials and observational studies.
  • Analysis of data on efficacy endpoints (e.g., clinical remission, endoscopic improvement) and safety profiles.
  • Evaluation of specific IL-23p19 inhibitors including risankizumab, mirikizumab, and guselkumab.

Main Results:

  • Risankizumab, mirikizumab, and guselkumab have shown significant efficacy and a favorable safety profile in IBD management.
  • IL-23p19 inhibitors represent a successful new class of biologics for treating IBD.
  • These agents contribute to the expanding therapeutic options for IBD patients.

Conclusions:

  • IL-23p19 inhibitors are effective and safe for IBD management.
  • The introduction of IL-23p19 inhibitors broadens treatment choices and may be beneficial in dual therapy regimens.
  • Further research may explore optimal use and combination strategies for IL-23p19 inhibitors in IBD.